Bristol-Myersstock has declined 1% in the year so far, against the industry’s 10.7% gain. Opdivo faces stiff competition from Merck &Co’s (MRK - Free …
Bristol Myers Squibbco now has $94.49B valuation. Muhlenkamp Inc invested in 3.3% or 178,961 shares. It has underperformed by 39.89% the S&P500. The institutional investor owned 4,543 shares of the biopharmaceutical …
The stock has "Hold" rating by Cowen & Co on Monday, July 10. Moreover, Atlantic Trust Grp Ltd Company has 0.15% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 389,523 shares. Holland Capital Management Llc acquired …
Berenberg had a markedly different take on 11/08/2016, proposing that BMY is …
It has underperformed by 39.89% the S&P500. Bristol-Myers Squibb Company …
Tenneco Inc now has $2.97B valuation. The share price as presented is an accounting quirk resulting from the total outstanding shares a company's board of directors has permitted to exist through its use of things such as stock splits. …
Denver Investment Advisors Llc sold 52,851 shares as Bristol (BMY)'s stock declined 1.04%. Philadelphia Trust Co. now owns 20,924 shares of the biopharmaceutical company's stock valued at $1,223,000 after buying an additional 1,500 …
Relative Strength Index (RSI) for Bristol-Myers Squibb Company (BMY) is at …
... Myers Squibb (BMY) toppled late Tuesday on mixed results from a Phase 3 …
It has underperformed by 39.89% the S&P500. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned "Buy" rating by Leerink Swann on Thursday, July 27. Bristol-Myers Squibb Company (NYSE:BMY) ended its day at $56.59 with the …